Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00121381
Status:
COMPLETED
Last Update Posted:
2008-01-15
First Post:
2005-07-14
Brief Title:
Pimecrolimus Cream 1 Plus Topical Corticosteroid in Patients 2-17 Years of Age With Severe Atopic Dermatitis
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
Pimecrolimus Cream 1 Plus Topical Corticosteroid in Patients 2-17 Years of Age With Severe Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Atopic dermatitis also called eczema is characterized by redness papulation skin elevation and pruritus skin itching The active ingredient of pimecrolimus inhibits the T-cell activation These cells are involved in the inflammatory component of the disease This study will test the safety of pimecrolimus Cream 1 with topical corticosteroid treatment commonly used in eczema in patients with severe atopic dermatitis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None